Details of the Drug
General Information of Drug (ID: DMMYENH)
Drug Name |
5-cyclohexyl-1,3,4-oxadiazole-2(3H)-thione
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
5-cyclohexyl-1,3,4-oxadiazole-2-thiol; 173589-87-2; 5-Cyclohexyl-[1,3,4]oxadiazole-2-thiol; CHEMBL456586; 5-cyclohexyl-1,3,4-oxadiazole-2(3H)-thione; 1,3,4-Oxadiazole-2(3H)-thione, 5-cyclohexyl-; BAS 09627004; AC1Q7GLG; AC1MWQ13; MLS000719170; SCHEMBL13401036; CTK0A7651; DTXSID20396654; MolPort-000-932-255; HMS1700P22; HMS2732D23; ZINC6675630; BDBM50320725; AKOS000669727; MCULE-5633296933; SMR000291438; KB-124591; 5-cyclohexyl-3H-1,3,4-oxadiazole-2-thione; EN300-10672; 5-Cyclohexyl-3H-[1,3,4]oxadiazole-2-thione; K-5320
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 184.26 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.5 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||